On January 8, 2016, Mylan N.V. and Momenta Pharmaceuticals, Inc. entered into an exclusive global collaboration agreement to jointly develop, manufacture, and commercialize six of Momenta’s current biosimilar medications. According to public information about the agreement, while each company will equally share costs and profits with respect to the products, Mylan will make an upfront cash payment of $45 million to Momenta, and could pay up to $200 million if certain milestones are reached. The parties also reported publicly that Mylan will lead worldwide commercialization efforts, and Momenta has an option to co-commercialize any approved products in the United States.
The deal includes a biosimilar for ORENCIA® (abatacept), a rheumatoid arthritis treatment. The companies did not identify the other five biosimilars in the deal.
Stay tuned to the Big Molecule Watch for further developments.